J Nucl Med 2013; 54:18691875
J Nucl Med 2013; 54:18691875. may result in enhanced treatment effectiveness. The pharmacokinetic profile of antibodies demands the use of long half-life isotopes for longitudinal scrutiny of mAb biodistribution and precludes the use of well-stablished short half-life isotopes. Herein, we review probably the most encouraging PET radiometals with chemical and physical characteristics that make the appealing for mAb labeling, highlighting those with theranostic radioisotopes. == 1 | Intro == Monoclonal antibodies (mAbs) have become indispensable tools for the modern clinical management of cancer. Currently, approximately 76 mAbs or antibody-related therapeutics have been approved by L-methionine the US Food and Drug Administration (FDA) and the Western Medicines Agency (EMA) for the treatment of several main and metastatic malignancy types. Some of the advantages of mAbs as restorative providers include an exquisite…